SCI时时刷

search
SMAGP regulates doxorubicin sensitivity in triple-negative breast cancer cells via modulating mitochondrial respiration
SMAGP regulates doxorubicin sensitivity in triple-negative breast cancer cells via modulating mitochondrial respiration
Doxorubicin-based chemotherapy remains as a major therapeutic approach for patients with triple-negative breast cancer (TN...
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial
Pemetrexed is a chemotherapeutic drug in the treatment of non-small cell lung cancer and mesothelioma. Optimized dosing of...
Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype
Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype
Dihydropyrimidine dehydrogenase (DPYD) is the rate-limiting step in fluoropyrimidines metabolism. Currently, genotype-guid...
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors
Combination treatment using lenvatinib (a multikinase inhibitor) plus pembrolizumab (a programmed death-1 immune checkpoin...
Absorption, distribution, metabolism, and excretion of [14C]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats
Absorption, distribution, metabolism, and excretion of [14C]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats
Mefuparib (CVL218) is a novel second-generation poly-ADP-ribose polymerase (PARP) inhibitor for cancer treatment. CVL218 c...
An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16
An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16
Among children, glioblastomas (GBMs) are a relatively common type of brain tumor. BRD4 expression was elevated in GBM and ...
Effects of vitamin E in preventing taxane‑induced peripheral neuropathy
Effects of vitamin E in preventing taxane‑induced peripheral neuropathy
Heiba MA, Ismail SS, Sabry M, Bayoumy WAE, Kamal KA (2021) The use of vitamin E in preventing taxane-induced peripheral ne...
Idiopathic hyperammonemic encephalopathy secondary to gemcitabine–cisplatin treatment
Idiopathic hyperammonemic encephalopathy secondary to gemcitabine–cisplatin treatment
Idiopathic hyperammonemic encephalopathy is a rare complication of chemotherapy, which has previously mainly been associat...
Re-thinking the possible interaction between proton pump inhibitors and capecitabine
Re-thinking the possible interaction between proton pump inhibitors and capecitabine
Proton Pump Inhibitors (PPI) rank within the top ten most prescribed medications in Europe and USA. A high frequency of PP...
The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects
The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects
Famitinib is an oral, small-molecule, multi-targeted tyrosine kinase inhibitor under clinical investigation for the treatm...
Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole
Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole
The DNA alkylating agent temozolomide (TMZ), is the first-line therapeutic for the treatment of glioblastoma (GBM). Howeve...
Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors
Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors
Cisplatin-etoposide treatment is recommended as a first line in small cell lung cancer patients (SCLC). However, the progn...
Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults
Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults
Fedratinib is an orally administered Janus kinase (JAK) 2–selective inhibitor for the treatment of adult patients wi...